OKYO Pharma’s Chairman Increases Stake Amidst Phase 2 Trial Completion

OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has issued an update.

On December 3, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 27,051 of the company’s ordinary shares on NASDAQ, increasing his total holdings to 10,491,746 shares. This acquisition underscores confidence in OKYO’s strategic direction, particularly as it advances urcosimod, which recently completed a Phase 2 trial for neuropathic corneal pain, potentially strengthening its market position in the ophthalmology sector.

The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical stage biopharmaceutical company listed on NASDAQ, focusing on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is working on urcosimod, a novel drug candidate designed to treat these ocular conditions by leveraging its anti-inflammatory and pain-reducing properties.

Average Trading Volume: 129,673

Technical Sentiment Signal: Hold

Current Market Cap: $69.96M

For detailed information about OKYO stock, go to TipRanks’ Stock Analysis page.